Unlock stock picks and a broker-level newsfeed that powers Wall Street.
NYSE American - Delayed Quote USD

NovaBay Pharmaceuticals, Inc. (NBY)

Compare
0.5720
-0.0131
(-2.24%)
At close: April 2 at 4:00:00 PM EDT
0.5800
+0.01
+(1.40%)
After hours: April 2 at 7:50:46 PM EDT
Loading Chart for NBY
  • Previous Close 0.5851
  • Open 0.5700
  • Bid --
  • Ask --
  • Day's Range 0.5720 - 0.5851
  • 52 Week Range 0.3600 - 9.1000
  • Volume 25,097
  • Avg. Volume 212,510
  • Market Cap (intraday) 3.327M
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) --
  • EPS (TTM) -74.6100
  • Earnings Date Apr 4, 2025 - Apr 9, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 0.85

NovaBay Pharmaceuticals, Inc. develops and sells eyecare and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; Avenova Eye Health Support antioxidant-rich oral supplements; Avenova Lubricating Eye Drops for instant relief; NovaWipes by Avenova; Avenova WarmEye Compress to soothe the eyes; and the i-Chek by Avenova to monitor physical eyelid health. The company also provides wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands. It sells its products through the company's web stores, third-party online retailers and distribution partners. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.

novabay.com

--

Full Time Employees

December 31

Fiscal Year Ends

Recent News: NBY

View More

Performance Overview: NBY

Trailing total returns as of 4/2/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

NBY
4.67%
S&P 500 (^GSPC)
3.58%

1-Year Return

NBY
83.66%
S&P 500 (^GSPC)
8.94%

3-Year Return

NBY
99.84%
S&P 500 (^GSPC)
24.75%

5-Year Return

NBY
99.94%
S&P 500 (^GSPC)
124.42%

Compare To: NBY

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: NBY

View More

Valuation Measures

Annual
As of 4/2/2025
  • Market Cap

    3.33M

  • Enterprise Value

    3.82M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    0.06

  • Price/Book (mrq)

    3.12

  • Enterprise Value/Revenue

    0.28

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -73.85%

  • Return on Assets (ttm)

    -49.91%

  • Return on Equity (ttm)

    -452.75%

  • Revenue (ttm)

    9.78M

  • Net Income Avi to Common (ttm)

    -5.83M

  • Diluted EPS (ttm)

    -74.6100

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    430k

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -93.75k

Research Analysis: NBY

View More

Company Insights: NBY

Research Reports: NBY

View More

People Also Watch